home / stock / rare / rare news

RARE News and Press, Ultragenyx Pharmaceutical Inc. From 05/22/23

Stock Information
Company Name: Ultragenyx Pharmaceutical Inc.
Stock Symbol: RARE
Market: NASDAQ
Website: ultragenyx.com
Menu
RARE RARE Quote RARE Short RARE News RARE Articles RARE Message Board
Get RARE Alerts

News, Short Squeeze, Breakout and More Instantly...
RARE - Ultragenyx: Despite OI Trial Doubts, This Is A Robust Rare Disease Company

2023-05-22 08:53:35 ET Summary Ultragenyx has a healthy rare disease product and pipeline. There are some issues with its next emerging catalyst. Despite those doubts, the company, as a whole, is very healthy. In November, I said that although I like Ultragenyx ( R...
RARE - Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit

NOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's c...

RARE - Ultragenyx gets FDA nod to amend dosing ranges in trial of neuro disorder drug

2023-05-17 08:46:05 ET Ultragenyx Pharmaceutical ( NASDAQ: RARE ) said the U.S. Food and Drug Administration (FDA) agreed to a protocol amendment to a phase 1/2 trial of GTX-102 in children with Angelman syndrome. The amendment allows the company to harmonize do...

RARE - Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.

NOVATO, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has reviewed and agreed to a protocol amendment to the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome that enabl...
RARE - Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting

NOVATO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultrarare diseases, today announced that clinical, preclinical and manufacturing data from it...

RARE - Ultragenyx to Present at Bank of America's 2023 Health Care Conference

NOVATO, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the co...

RARE - Ultragenyx Pharmaceutical GAAP EPS of -$2.33 misses by $0.33, revenue of $100.5M misses by $3.4M

2023-05-04 16:49:46 ET Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q1 GAAP EPS of -$2.33 misses by $0.33 . Revenue of $100.5M (+25.8% Y/Y) misses by $3.4M . First quarter 2023 total revenue of $100.5 million, Crysvita revenue of $76.0 million and ...
RARE - Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update

First quarter 2023 total revenue of $100.5 million, Crysvita ® revenue of $76.0 million and Dojolvi ® revenue of $14.3 million Total revenue grew 26% and Crysvita revenue grew 28% versus the first quarter 2022 Reaffirmed 2023 expected total revenue guidance bet...

RARE - Dennis Huang of Ultragenyx Named to MassBio's Board of Directors

BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced Dennis Huang, chief technical operations officer and executive v...

RARE - Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update

NOVATO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at ...
Previous 10 Next 10